NSCLC treatment

Jan 08, 2024

The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like sotorasib and adagrasib directly target KRAS G12C by forming a...

Nov 17, 2023

Lung cancer is the leading cause of cancer death in both men and women around the world. It is expected that 127K people will die from this disease in the United States in 2023 (67K men and 60K women).  NSCLC is the most common type of lung cancer, accounting for over 85% of all cases. As per DelveInsight anal...

Sep 08, 2023

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Mar 17, 2023

Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...

Nov 25, 2022

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 230K new cases were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year, accounting for almost 130K deaths. As per DelveIn...

Nov 25, 2022

Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...

Jan 14, 2022

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapi...